FDA notifies Amgen of misbranding of its biological product, Neulasta, due to false or misleading promotional communications about the product ’s benefit
The Food and Drug Administration (FDA) has issued an untitled letter to Amgen Inc. for the misbranding of its biological product, Neulasta (pegfilgrastim) injection, for subcutaneous use, resulting from a false or misleading promotional communication. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 14, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Experts discuss the importance of successful adoption of biosimilars in the US health care system
Since 2015, Kaiser Permanente has saved over $200 million throughout its health systems by adopting biosimilar medicines. Kaiser Permanente, a community-based, not-for-profit, integrated delivery system serving 12.4 million members started by implementing Zarxio® (filgrastim-sndz). Made by global health care company Sandoz, it was the first biosimilar approved in the U.S. The path toward acceptance of this medicine was rigorous. A biosimilar is designed to match and have no clinically meaningful… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 29, 2021 Category: Biotechnology Authors: Laura Newpoff Source Type: news

Experts discuss the importance of successful adoption of biosimilars in the US health care system
Since 2015, Kaiser Permanente has saved over $200 million throughout its health systems by adopting biosimilar medicines. Kaiser Permanente, a community-based, not-for-profit, integrated delivery system serving 12.4 million members started by implementing Zarxio® (filgrastim-sndz). Made by global health care company Sandoz, it was the first biosimilar approved in the U.S. The path toward acceptance of this medicine was rigorous. A biosimilar is designed to match and have no clinically meaningful… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 29, 2021 Category: American Health Authors: Laura Newpoff Source Type: news

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

Neulasta (pegfilgrastim)
Title: Neulasta (pegfilgrastim)Category: MedicationsCreated: 3/19/2021 12:00:00 AMLast Editorial Review: 3/19/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 19, 2021 Category: Cancer & Oncology Source Type: news

Nivestym (Filgrastim-aafi Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 20, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Nyvepria (pegfilgrastim-apgf), a Biosimilar to Neulasta
NEW YORK--(BUSINESS WIRE)-- June 11, 2020 -- Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Nyvepria (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegfilgrastim).1 Nyvepria is... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 11, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
Holzkirchen, Nov. 5, 2019– Sandoz, a Novartis division and a global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar Ziextenzo (pegfilgrastim-bmez). Sandoz biosimilar pegfilgrastim... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 5, 2019 Category: Drugs & Pharmacology Source Type: news

Novartis finally wins US approval for its generic Neulasta
The drugmaker ' s biosimilar Ziextenzo was originally rejected by the FDA in 2016 (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 5, 2019 Category: Pharmaceuticals Source Type: news

Novartis gets U.S. nod for long-delayed Amgen copycat
Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in its uphill battle to sell copies of rivals' blockbusters in the world's top drug market. (Source: Reuters: Health)
Source: Reuters: Health - November 5, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

filgrastim (Neupogen)
Title: filgrastim (Neupogen)Category: MedicationsCreated: 9/19/2000 12:00:00 AMLast Editorial Review: 8/2/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 2, 2019 Category: Cancer & Oncology Source Type: news

Savings With Biosimilar Filgrastim Unclear Savings With Biosimilar Filgrastim Unclear
Projected cost savings from switching to biosimilar filgrastim from the reference drug depend on the data analyzed.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries
Amgen Donates $93 Million Worth of Cancer Medicines THOUSAND OAKS, Calif. and SANTA BARBARA, Calif., Dec. 13, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Direct Relief today announced a joint initiative in which Direct Relief will distribute $93 million worth of Amgen donated cancer treatments and supportive care medicines. This donation will provide cancer patients in 18 developing countries access to Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim) and Vectibix® (panitumumab). Patients will access the donated medicines through Direct Relief-partner hospitals and clinics in the following countries: Armenia, Ca...
Source: Amgen News Release - December 13, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Early Insights into Biosimilar Cost Savings in the United States
A recent study inJAMA Oncologyexamined the average daily cost of  biosimilar filgrastim-sndz compared with the brand name biologic. (Source: CancerNetwork)
Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. (Source: Reuters: Health)
Source: Reuters: Health - November 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news